Relay Therapeutics IPO

7/15/2020

IPO

$400,000,000

Per the firm's most recent regulatory filing, it plans to use the net proceeds as follows: to fund the remainder of our Phase 1 and Phase 1b exploratory trials for RLY-1971 and a portion of our confirmatory Phase 2/3 trials; to fund our Phase 1 exploratory trial for RLY-4008 and a portion of our confirmatory Phase 2/3 trials; to identify a lead development candidate and conduct IND-enabling studies for RLY-PI3K1047 and a portion of our Phase 1 and Phase 1b exploratory trials; for the continued development of our discovery programs; and the remaining proceeds for general corporate purposes, which may include the hiring of additional personnel, capital expenditures and the costs of operating as a public company.

Publicly-held

Biopharmaceutical

215 1st St. 3rd Floor
Cambridge, MA 02142
USA

Relay Therapeutics (Nasdaq: RLAY) is committed to discovering and developing medicines that will make a transformative difference for patients by building the first dedicated drug discovery pipeline centered on protein motion.